Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
By D. Franz, E. Belousova, S. Sparagana, E. Bebin, M. Frost, R. Kuperman, O. Witt, Michael H. Kohrman, J. Flamini, Joyce Y. Wu and 10 more. The Lancet, 2013
712 citations recorded by the source corpus.
Subfields: Molecular Biology, Neurology, Physiology
View Paper: https://www.semanticscholar.org/paper/ebdf9a78edb944e22d73e992ffe3d21a797fc178
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Neurology
In Physiology
Citations in the corpus
- Tuberous Sclerosis Complex Surveillance and Management: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference (2013, background): “Twelve subcommittees, each led by a clinician with advanced expertise in TSC and the relevant medical subspecialty, were organized to focus on specific disease focus topics that have important clinical management implications in TSC: (1) dermatology and dentistry; (2) nephrology; (3) pulmonology; (4”
- Tuberous Sclerosis Complex Diagnostic Criteria Update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference (2013, neutral): “The individual panels were organized as follows: (1) dermatology and dentistry; (2) ophthalmology; (3) brain structure, tubers, and tumors; (4) epilepsy; (5) TSC-associated neuropsychiatric disorders; (6) cardiology; (7) pulmonology; (8) nephrology; (9) endocrinology; (10) gastroenterology; and (11)”